Free Trial
One Day Left! MarketBeat All Access Returns to $249 Soon
  • 0Days
  • 0Hours
  • 0Minutes
  • 0Seconds
Don't Miss Out
Claim MarketBeat All Access Sale Promotion
NASDAQ:ARCT

Arcturus Therapeutics Q3 2026 Earnings Date & Estimates

Arcturus Therapeutics logo
$12.22 +0.16 (+1.28%)
As of 11:21 AM Eastern
This is a fair market value price provided by Massive. Learn more.

Arcturus Therapeutics is scheduled to report Q3 2026 earnings on Thursday, November 5, 2026, after market closes. The conference call is scheduled for 4:30 PM ET.

Research:ProfileEarnings HistoryForecast

Upcoming Earnings Announcement

Quarter
Q3 2026
Announcement Date
Time
After Market Closes
Conference Call
4:30 PM ET
Google Calendar (opens in a new tab)Outlook (opens in a new tab)Yahoo Calendar (opens in a new tab)

What Analysts Expect from Arcturus Therapeutics in Q3 2026

Arcturus Therapeutics is expected to post earnings of -$0.6804 per share on revenue of $8.00 million. In the same quarter a year earlier Arcturus Therapeutics reported -$0.49 per share on revenue of $17.15 million. Arcturus Therapeutics last reported on August 7, 2026, posting -$0.84 per share and beating the -$0.9964 consensus estimate. Arcturus Therapeutics has beaten the consensus EPS estimate in 6 of its last 8 quarters.

Consensus Estimates

Consensus EPS
-$0.6804
Expected Revenue
$8.00 million
Prior-Year EPS
-$0.49
Prior-Year Revenue
$17.15 million
Expected Revenue Growth
-53.4%

Recent Track Record

Last Reported
Q2 2026
Last Quarter EPS
-$0.84 (Beat by +$0.1564)
Last Quarter Revenue
$2.96 million
EPS Beat Rate
6 of last 8 quarters

Prepare for the Q3 2026 Call

Arcturus Therapeutics Q3 2026 Earnings FAQ

Arcturus Therapeutics (NASDAQ:ARCT) has confirmed it will report Q3 2026 earnings on Thursday, November 5, 2026, after market closes.

Arcturus Therapeutics' Q3 2026 earnings conference call is scheduled for Thursday, November 5, 2026 at 4:30 PM ET. MarketBeat streams the conference call audio and posts the transcript as soon as possible on the earnings announcement date.

Analysts expect Arcturus Therapeutics to post earnings of -$0.6804 per share for Q3 2026.

The consensus revenue estimate for Arcturus Therapeutics is $8.00 million for Q3 2026.

Arcturus Therapeutics Earnings Headlines

Arcturus Therapeutics to Report Third Quarter Financial Results and Provide Corporate Update on November 5, 2026
October 26 at 5:09 PM  |  finance.yahoo.comhttps://finance.yahoo.com/healthcare/articles/arcturus-therapeutics-report-third-quarter-200100252.html
Wells Fargo Keeps Their Buy Rating on Arcturus Therapeutics (ARCT)
October 6, 2026  |  theglobeandmail.comhttps://www.theglobeandmail.com/investing/markets/markets-news/Tipranks/4981132/wells-fargo-keeps-their-buy-rating-on-arcturus-therapeutics-arct/
The Claude AI company doubled in value... you missed it
In May, Anthropic raised money at a $965 billion valuation. Now, ahead of its IPO, investors are reportedly discussing a valuation of $1.8 to $2 trillion. That’s roughly double in about five months. And not one ordinary investor got to own a share of it. That’s how these mega-IPOs work. The biggest gains happen privately, before the public is allowed in. By the time you can buy, the price already assumes almost everything goes right. So I’m not chasing the IPO. I’m watching where the private investors who already doubled their money put their winnings next.tc pixel
October 29 at 1:00 AM  |  Crypto 101 Media (Ad)
Analysts Offer Insights on Healthcare Companies: Amgen (AMGN) and Arcturus Therapeutics (ARCT)
October 3, 2026  |  theglobeandmail.comhttps://www.theglobeandmail.com/investing/markets/stocks/AMGN/pressreleases/4942111/analysts-offer-insights-on-healthcare-companies-amgen-amgn-and-arcturus-therapeutics-arct/
Analysts Are Bullish on Top Healthcare Stocks: Arcturus Therapeutics (ARCT), ACADIA Pharmaceuticals (ACAD)
September 25, 2026  |  theglobeandmail.comhttps://www.theglobeandmail.com/investing/markets/stocks/ACAD/pressreleases/4801079/analysts-are-bullish-on-top-healthcare-stocks-arcturus-therapeutics-arct-acadia-pharmaceuticals-acad/
Arcturus Therapeutics Shares Rise After OTC Deficiency Data, Citigroup Upgrade
September 24, 2026  |  marketscreener.comM
See More Arcturus Therapeutics Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Arcturus Therapeutics? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Arcturus Therapeutics and other key companies, straight to your email.

About Arcturus Therapeutics

Arcturus Therapeutics (NASDAQ:ARCT) is a biotechnology company headquartered in San Diego, California, focused on developing medicines based on messenger RNA (mRNA) and other RNA technologies. The company’s platform includes LUNAR, a lipid-mediated delivery system designed to transport nucleic acids into cells, as well as technologies for producing and administering mRNA and self-amplifying RNA.

The company’s development programs address infectious diseases and rare genetic disorders. Arcturus has developed KOSTAIVE, a self-amplifying mRNA COVID-19 vaccine known as ARCT-154, in collaboration with CSL. The company is also advancing investigational RNA medicines for conditions including ornithine transcarbamylase deficiency and cystic fibrosis, among other potential applications.

Arcturus was founded in 2013 and has pursued partnerships and licensing arrangements to support the development and commercialization of its RNA-based products. Its programs are intended for patients in the United States and international markets, with regulatory and commercial activities varying by product and geography. Joseph Payne serves as the company’s president and chief executive officer.

View Arcturus Therapeutics Profile
Earnings Tools